Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 28;24(13):10766.
doi: 10.3390/ijms241310766.

Gene Therapy Approaches for the Treatment of Hemophilia B

Anastasiia B Soroka  1 , Sofya G Feoktistova  1 , Olga N Mityaeva  1 , Pavel Y Volchkov  1
Affiliations
Review

Gene Therapy Approaches for the Treatment of Hemophilia B

Anastasiia B Soroka et al. Int J Mol Sci. .

Abstract

In contrast to the standard enzyme-replacement therapy, administered from once per 7-14 days to 2-3 times a week in patients with severe hemophilia B, as a result of a single injection, gene therapy can restore F9 gene expression and maintain it for a prolonged time. In clinical research, the approach of delivering a functional copy of a gene using adeno-associated viral (AAV) vectors is widely used. The scientific community is actively researching possible modifications to improve delivery efficiency and expression. In preclinical studies, the possibility of genome editing using CRISPR/Cas9 technology for the treatment of hemophilia B is also being actively studied.

Keywords: AAV; blood coagulation factor IX; gene therapy; genome editing; hemophilia B; hemostasis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Goodeve A.C. Hemophilia B: Molecular Pathogenesis and Mutation Analysis. J. Thromb. Haemost. 2015;13:1184. doi: 10.1111/jth.12958. - DOI - PMC - PubMed
    1. Miller C.H., Bean C.J. Genetic Causes of Haemophilia in Women and Girls. Haemophilia. 2021;27:e164. doi: 10.1111/hae.14186. - DOI - PMC - PubMed
    1. Diagnosis & Severity of Registry Participants | Males With Hemophilia Registry Report 2014-2017 | CDC. [(accessed on 20 June 2023)]; Available online: https://www.cdc.gov/ncbddd/hemophilia/communitycounts/registry-report-ma....
    1. Lambert T., Benson G., Dolan G., Hermans C., Jiménez-Yuste V., Ljung R., Morfini M., Zupančić-Šalek S., Santagostino E. Practical Aspects of Extended Half-Life Products for the Treatment of Haemophilia. Ther. Adv. Hematol. 2018;9:295. doi: 10.1177/2040620718796429. - DOI - PMC - PubMed
    1. Santagostino E., Martinowitz U., Lissitchkov T., Pan-Petesch B., Hanabusa H., Oldenburg J., Boggio L., Negrier C., Pabinger I., Von Depka Prondzinski M., et al. Long-Acting Recombinant Coagulation Factor IX Albumin Fusion Protein (RIX-FP) in Hemophilia B: Results of a Phase 3 Trial. Blood. 2016;127:1761–1769. doi: 10.1182/blood-2015-09-669234. - DOI - PMC - PubMed